RBC Capital analyst Alistair Campbell lowered the firm’s price target on Genmab (GMAB) to DKK 2,300 from DKK 2,400 and keeps an Outperform rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab price target lowered to $45 from $50 at Truist
- William Blair upgrades Genmab with focus now on pipeline
- Genmab upgraded to Outperform from Market Perform at William Blair
- Expectations for J&J Genmab opt-in lowered ahead of news, says Morgan Stanley
- JPMorgan expects ‘significant’ underperformance of Genmab shares